CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY AND DEFICIT - USD ($)	Convertible Redeemable Preferred Stock Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at the beginning at Dec. 31, 2023	$ 408,982
Balance at the beginning (in shares) at Dec. 31, 2023	10,022
Increase (Decrease) in Temporary Equity
Accrual of Series A Preferred Stock and dividend redemption	$ (840,353)
Accrual of Series A Preferred Stock and dividend redemption (in shares)	(709)
Series A Preferred Stock accretion	$ 5,268,776
Series A Preferred Stock dividends	$ 601,120
Preferred Stock redemption including cash premium		$ 15	$ 5,452,086		$ 5,452,101
Preferred Stock redemption including cash premium (in share)	3,650	152,506
Deemed dividend (Series A Preferred Warrants)			5,615		5,615
Preferred Stock redemption including cash premium	$ (4,531,546)
Balance at the end at Mar. 31, 2024	$ 5,663
Balance at the end (in shares) at Mar. 31, 2024	906,979
Balance at the beginning at Dec. 31, 2023		$ 12	110,960,610	$ (98,889,581)	12,071,041
Balance at the beginning (in shares) at Dec. 31, 2023		119,655
Increase (Decrease) in Stockholders' Equity
Stock-based compensation expense			180,381		180,381
Common Stock issued for services			110,000		110,000
Common Stock issued for services (in shares)		3,113
Series A Preferred Stock accretion			(5,268,776)		(5,268,776)
Series A Preferred Stock dividends			(601,120)		(601,120)
Net loss				(2,162,663)	(2,162,663)
Balance at the end at Mar. 31, 2024		$ 27	110,838,796	(101,052,244)	$ 9,786,579
Balance at the end (in shares) at Mar. 31, 2024		275,274
Balance at the beginning (in shares) at Dec. 31, 2024					0
Increase (Decrease) in Temporary Equity
Preferred Stock redemption including cash premium		$ 3	338,518		$ 338,521
Preferred Stock redemption including cash premium (in share)		31,638			31,628
Deemed dividend (Series A Preferred Warrants)					$ 8,400,000
Balance at the end (in shares) at Mar. 31, 2025					0
Balance at the beginning at Dec. 31, 2024		$ 42	105,740,751	(113,208,371)	$ (7,467,578)
Balance at the beginning (in shares) at Dec. 31, 2024		421,124
Increase (Decrease) in Stockholders' Equity
Stock-based compensation expense			80,038		80,038
Common Stock and prefunded warrants issued, net of expenses		$ 160	(160)
Common Stock and prefunded warrants issued, net of expenses (in shares)		1,600,000
Series A Preferred Stock dividends			(275,167)		(275,167)
Net loss				(2,260,022)	(2,260,022)
Balance at the end at Mar. 31, 2025		$ 205	$ 105,883,980	$ (115,468,393)	$ (9,584,208)
Balance at the end (in shares) at Mar. 31, 2025		2,052,762

Petros Pharmaceuticals, Inc. 10-Q